Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
SAN DIEGO, May 02, 2018 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results for the first quarter 2018 as well as provide a corporate update at 4:30 p.m. EDT on May 9, 2018.
The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 3689458. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for otology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
619.849.5377
[email protected]
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]
